Diabetes Update: New Data Shows How Abbott's Health Tech Helps More People, In More Places

Diabetes Update: New Data Shows How Abbott's Health Tech Helps More People, In More Places

At ADA's Scientific Sessions, new data show how our CGM system helps more people in more places.

At ADA's Scientific Sessions, new data show how our CGM system helps more people in more places.

Friday, July 16, 2021 - 9:05am

CONTENT: Blog

Ask anyone managing diabetes for their number, the first response won't be their digits for a date.

You might get a "1." Or a "2." Or their A1c.

Knowing those diabetes numbers is crucial to the health of millions living with diabetes and with technology like the FreeStyle Libre continuous glucose monitoring system, it's never been easier, affordable and accessible for so many.

And now, we have more data1,2,3 presented at the American Diabetes Association's 81st Scientific Sessions that demonstrate the difference made by reducing HbA1C while lessening hypoglycemia and hyperglycemia for the people who need it the most.

  • Demographic data show FreeStyle Libre users reflect the diverse U.S. population living with type 1 and type 2 diabetes, including older people, those living in rural areas, people of color and those with higher rates of comorbidities.1,2
  • Priced at a third of the cost of other CGMs,4 it's widely available and accessible, reaching more diverse and at-risk populations than other systems.
  • Cost analysis data show increasing the number of people using FreeStyle Libre by just 10% could save Medicaid $23 million a year3 due to the reduction in complications among Americans living with diabetes who rely on Medicaid.

Bringing breakthrough diabetes care technologies where they're needed most is the focus of Abbott's work with the American Diabetes Association to counter COVID-19's effects on the community. As the first anchor sponsor of the ADA's Health Equity Now initiative, the company is making a commitment of $5 million over three years to bring improved, equitable diabetes care to underserved communities and low-income Americans — 75% of whom are people of color.

The numbers of people we can help with our FreeStyle Libre system are what matter most.

So ask us our diabetes numbers and that's what you'll hear first.

References

1Miller et al. A Comparison of Continues Glucose Monitors in Reducing A1c in Type 1 and Type 2 Diabetes: FreeStyle Libre® and Dexcom.
2Hirsch et al. Acute Diabetes Events and All-Cause Hospitalizations among Continuous Glucose Monitoring Device Recipients with Type 1 and Type 2 Diabetes: A Comparison of FreeStyle Libre® and Dexcom.
3Frank et al. Budget Impact of Adding Flash Continuous Glucose Monitoring (CGM) to Medicaid.
4Based on a comparison of list prices of the FreeStyle Libre portfolio versus competitor CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

IMPORTANT SAFETY INFORMATION

FREESTYLE LIBRE 14 DAY SYSTEM

Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/us-en/safety-information.html for safety info.

FREESTYLE LIBRE 2 SYSTEM

Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/us-en/safety-information.html for safety info.